Clinical Trials Logo

Filter by:
NCT ID: NCT01029145 Completed - Bipolar Disorder Clinical Trials

Management of Index Episode in Patients With Bipolar Disorder Treated by Seroquel XR

Start date: December 2009
Phase: N/A
Study type: Observational

The primary purpose of the study is to explore management of symptomatology in patients with bipolar disorder that experience a new manic,depressive or mixed episode and are treated with Seroquel XR monotherapy/adjuctive, in routine clinical practice in Romania

NCT ID: NCT01027871 Completed - Clinical trials for Diabetes Mellitus, Type 2

A Study for Patients With Type 2 Diabetes

Start date: January 2010
Phase: Phase 2
Study type: Interventional

Comparison of fasting blood glucose levels in patients with Type 2 diabetes after 12 weeks of treatment with a new basal insulin analog or with insulin glargine.

NCT ID: NCT01027728 Completed - Clinical trials for Rheumatoid Arthritis

Study to Evaluate Safety and Efficacy of CCX 354-C in Subjects With Rheumatoid Arthritis

CARAT-1
Start date: December 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of multiple oral doses of CCX354-C at a number of dose levels in subjects with stable rheumatoid arthritis (RA).

NCT ID: NCT01026142 Completed - Breast Cancer Clinical Trials

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Start date: January 26, 2010
Phase: Phase 3
Study type: Interventional

This randomized, two-arm study evaluated the efficacy and safety of a combination of trastuzumab and capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. The study population consisted of female patients, whose disease had progressed during or following previous trastuzumab therapy for metastatic disease. All patients in Arm A and Arm B received trastuzumab (8 mg/kg iv as loading dose and then 6 mg/kg iv every 3 weeks thereafter) and capecitabine oral twice daily for 14 days every 3 weeks (1250 mg/m2 twice daily in Arm A and 1000 mg/m2 twice daily in Arm B). In addition, patients in Arm B received pertuzumab (840 mg iv as loading dose and then 420 mg iv thereafter) every 3 weeks. Study treatment continued until disease progression or unacceptable toxicity.

NCT ID: NCT01025284 Completed - Clinical trials for Small Cell Lung Cancer

A Study for Participants With Small-Cell Lung Cancer

Start date: December 2009
Phase: Phase 2
Study type: Interventional

Part A: This study evaluates an experimental treatment in participants with extensive-disease in small-cell lung cancer. Part B: This study evaluates an experimental treatment in participants with extensive-disease in small-cell lung cancer.

NCT ID: NCT01024920 Completed - Clinical trials for Carcinoma, Renal Cell

Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.

Start date: December 16, 2009
Phase: Phase 2
Study type: Interventional

Compare safety and efficacy of BIBF 1120 versus sunitinib in patients with advanced RCC and to investigate the effects of BIBF 1120 on the heart rate (HR) corrected QT interval (QTcF).

NCT ID: NCT01023581 Completed - Clinical trials for Diabetes Mellitus, Type 2

Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes

AM7D
Start date: November 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of alogliptin combined with metformin, once daily (QD) or twice daily (BID), in participants with Type 2 Diabetes.

NCT ID: NCT01023516 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/Formoterol

Start date: November 2009
Phase: Phase 2
Study type: Interventional

The primary objective is to evaluate the efficacy of AZD9668 compared with placebo in symptomatic COPD patients by assessing the effects on lung function and symptoms of COPD

NCT ID: NCT01020448 Completed - Prostate Cancer Clinical Trials

Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer

Triptocare
Start date: November 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effect of an initial hormonal treatment gonadotrophin-releasing hormone (GnRH Agonist) on 2 biomarkers (PCA3 and TMPRSS2-ERG), in patients with histologically confirmed and advanced stages of prostate cancer. Their characteristics, according to risk factors such as PSA and Gleason score will be determined at baseline and 1, 3 and 6 month post-treatment.

NCT ID: NCT01020123 Completed - Clinical trials for Type II Diabetes Mellitus

Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients

Start date: October 2009
Phase: Phase 2
Study type: Interventional

The primary aim is to evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in TD2M Patients